Investor Presentation First Nine Months of 2023
Novo NordiskⓇ
International Operations diabetes care sales growth is driven by
GLP-1 performance
7
Investor presentation
First nine months of 2023
Reported Diabetes care sales and growth per IO geography
GLP-1 patients and value market share in IO
DKK
billion
Insulin GLP-1 Growth at CER
Number of
patients (millions)
Value
market share
Class growth >35%
60
21%
8
75%
68.7%
50
50
40
40
30
30
4
6
60%
Geographical regions
23%
20
20
50%
26%
-1%
13%
2
61%
10
95%
2%
-10%
5%
0
0
Aug
IO
EMEA
China
ROW
2021
GLP-1 patients
-Rybelsus®
Aug
2022
-OzempicⓇ
-dulaglutide
-NN GLP-1
IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; CER: Constant exchange rates
Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Jun'23-Aug'23 vs Jun'22-Aug 22 (Rolling 3-month average)
Source: IQVIA MAT, Aug 2023 (Spot rate). Volume packs are converted into full-year patients based on WHO assumptions for average daily doses; Market values are based on the list prices
60%
45.8%
45%
27.5%
30%
12.4%
15%
10.5%
2.3%
0%
Aug
2023
-VictozaⓇ
―tirzepatideView entire presentation